Literature DB >> 29565840

Fatal Yellow Fever in Travelers to Brazil, 2018.

Davidson H Hamer, Kristina Angelo, Eric Caumes, Perry J J van Genderen, Simin A Florescu, Corneliu P Popescu, Cecilia Perret, Angela McBride, Anna Checkley, Jenny Ryan, Martin Cetron, Patricia Schlagenhauf.   

Abstract

Yellow fever virus is a mosquito-borne flavivirus that causes yellow fever, an acute infectious disease that occurs in South America and sub-Saharan Africa. Most patients with yellow fever are asymptomatic, but among the 15% who develop severe illness, the case fatality rate is 20%-60%. Effective live-attenuated virus vaccines are available that protect against yellow fever (1). An outbreak of yellow fever began in Brazil in December 2016; since July 2017, cases in both humans and nonhuman primates have been reported from the states of São Paulo, Minas Gerais, and Rio de Janeiro, including cases occurring near large urban centers in these states (2). On January 16, 2018, the World Health Organization updated yellow fever vaccination recommendations for Brazil to include all persons traveling to or living in Espírito Santo, São Paulo, and Rio de Janeiro states, and certain cities in Bahia state, in addition to areas where vaccination had been recommended before the recent outbreak (3). Since January 2018, 10 travel-related cases of yellow fever, including four deaths, have been reported in international travelers returning from Brazil. None of the 10 travelers had received yellow fever vaccination.

Entities:  

Mesh:

Year:  2018        PMID: 29565840      PMCID: PMC5868208          DOI: 10.15585/mmwr.mm6711e1

Source DB:  PubMed          Journal:  MMWR Morb Mortal Wkly Rep        ISSN: 0149-2195            Impact factor:   17.586


Yellow fever virus is a mosquito-borne flavivirus that causes yellow fever, an acute infectious disease that occurs in South America and sub-Saharan Africa. Most patients with yellow fever are asymptomatic, but among the 15% who develop severe illness, the case fatality rate is 20%–60%. Effective live-attenuated virus vaccines are available that protect against yellow fever (). An outbreak of yellow fever began in Brazil in December 2016; since July 2017, cases in both humans and nonhuman primates have been reported from the states of São Paulo, Minas Gerais, and Rio de Janeiro, including cases occurring near large urban centers in these states (). On January 16, 2018, the World Health Organization updated yellow fever vaccination recommendations for Brazil to include all persons traveling to or living in Espírito Santo, São Paulo, and Rio de Janeiro states, and certain cities in Bahia state, in addition to areas where vaccination had been recommended before the recent outbreak (). Since January 2018, 10 travel-related cases of yellow fever, including four deaths, have been reported in international travelers returning from Brazil. None of the 10 travelers had received yellow fever vaccination. Five of the 10 cases were reported by ProMED since January 15, including two from Argentina and three from Chile; two of the travelers from Chile died. In addition, during January 1–March 15, 2018, five confirmed cases of yellow fever in unvaccinated travelers returning from Brazil were reported by GeoSentinel (http://www.istm.org/geosentinel), the global clinician-based sentinel surveillance system for travel-related illness among international travelers and migrants (). These five yellow fever cases represent the first such cases identified by GeoSentinel (Table), which was initiated in 1995 by the International Society of Travel Medicine with support from CDC and now consists of 70 specialized travel and tropical medicine clinical sites around the world. The first of the GeoSentinel-reported cases occurred in a Dutch man aged 46 years who traveled to São Paulo state for 3 weeks during December 2017–January 2018. The second case occurred in a French woman, aged 42 years, who traveled to Minas Gerais state in Brazil for 4 weeks during December 2017–January 2018. She received a diagnosis of yellow fever in Brazil and was examined at a GeoSentinel site after returning to France to convalesce. The third and fourth cases occurred in a Romanian man, aged 34 years, and a Swiss man, aged 44 years, each of whom visited Brazil for approximately 2 weeks in February 2018. The fifth case was in a German man, aged 33 years, who spent a week in Brazil in late February. The Swiss and German travelers died from their illness (Table).
TABLE

Characteristics of five travelers to Brazil with yellow fever reported by GeoSentinel sites, January–March 2018*

CharacteristicPatient 1 (man)Patient 2 (woman)Patient 3 (man)Patient 4 (man)Patient 5 (man)
Age (yrs)
46
42
34
44
33
Nationality
Dutch
French
Romanian
Swiss
German
Reporting site
Netherlands
France
Romania
Switzerland
United Kingdom
Area (state) of presumed yellow fever acquisition
Mairiporã (São Paulo)
(Minas Gerais)
Ilha Grande (Rio de Janeiro)
Ilha Grande (Rio de Janeiro)
Ilha Grande (Rio de Janeiro)
Signs/Symptoms
Fever, headache, myalgia, nausea, vomiting, diarrhea
Fever
Fever, rash, myalgia, encephalopathy
Fever, petechial rash, arthralgia, vomiting, diarrhea
Fever, malaise, nausea, jaundice, hepatomegaly
Clinical/Laboratory findings
Hepatitis
Hepatitis, thrombocytopenia, neutropenia
Renal and hepatic failure
Renal and hepatic failure
Thrombocytopenia, renal and hepatic failure
Yellow fever diagnostic testing
Positive RT-PCR for YFV (urine, whole blood, plasma)
Positive RT-PCR (blood); positive IgM (initial diagnosis made in Brazil)
Positive PCR (serum, urine); YF IgM positive; IgG titers rising days 4–8
Positive PCR (blood)
Positive RT-PCR (serum, urine)
Yellow fever vaccination status
No
No
No
No
No
Outcome RecoveredRecoveredCondition improving as of March 15, 2018DiedDied

Abbreviations: IgG = Immunoglobulin G; IgM = Immunoglobulin M; PCR = polymerase chain reaction; RT-PCR = reverse transcription–PCR; YF = yellow fever; YFV = YF virus.

* In addition to the five patients reported by GeoSentinel sites, five additional cases of yellow fever have been reported by ProMED among persons who traveled to Brazil from Argentina (two) and Chile (three) since January 2018. Two of the patients from Chile died.

Abbreviations: IgG = Immunoglobulin G; IgM = Immunoglobulin M; PCR = polymerase chain reaction; RT-PCR = reverse transcription–PCR; YF = yellow fever; YFV = YF virus. * In addition to the five patients reported by GeoSentinel sites, five additional cases of yellow fever have been reported by ProMED among persons who traveled to Brazil from Argentina (two) and Chile (three) since January 2018. Two of the patients from Chile died. Among the 10 international travelers reported with yellow fever acquired in Brazil, eight acquired the disease on Ilha Grande, a forested island off the Rio de Janeiro coast, where one human and one nonhuman primate yellow fever case were reported in early February 2018 (); of the eight patients who acquired the disease on Ilha Grande, four died. Another travel-related case of yellow fever was reported recently outside of Brazil (). Yellow fever is a potentially fatal illness that is preventable by vaccination. Yellow fever vaccination is recommended for all eligible persons aged ≥9 months, traveling to many areas in Brazil, including the states of São Paulo and Rio de Janeiro (especially Ilha Grande). Unvaccinated travelers should avoid traveling to areas where vaccination is recommended (https://wwwnc.cdc.gov/travel/notices). Travelers planning to visit areas in Brazil or elsewhere where yellow fever transmission is occurring should receive yellow fever vaccine at least 10 days before travel and follow recommendations for avoiding mosquito bites (https://www.cdc.gov/yellowfever/prevention/index.html). The Food and Drug Administration–approved yellow fever vaccine, YF-VAX, is currently unavailable in the United States because of manufacturing difficulties (). An alternative yellow fever vaccine, Stamaril, is available through a limited number of U.S. yellow fever vaccination clinics. U.S. travelers should therefore plan ahead to obtain Stamaril because it might take more time to access one of these clinics. Clinicians assessing returned travelers should be aware of yellow fever signs and symptoms and maintain vigilance regarding the possibility of yellow fever exposure in travelers returning from Brazil or other areas with ongoing transmission of yellow fever.
  3 in total

1.  Surveillance for travel-related disease--GeoSentinel Surveillance System, United States, 1997-2011.

Authors:  Kira Harvey; Douglas H Esposito; Pauline Han; Phyllis Kozarsky; David O Freedman; D Adam Plier; Mark J Sotir
Journal:  MMWR Surveill Summ       Date:  2013-07-19

2.  Addressing a Yellow Fever Vaccine Shortage - United States, 2016-2017.

Authors:  Mark D Gershman; Kristina M Angelo; Julian Ritchey; David P Greenberg; Riyadh D Muhammad; Gary Brunette; Martin S Cetron; Mark J Sotir
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-05-05       Impact factor: 17.586

3.  Notes from the Field: Fatal Yellow Fever in a Traveler Returning From Peru - New York, 2016.

Authors:  Alexandra P Newman; Rebecca Becraft; Amy B Dean; Rene Hull; Bryon Backenson; Gillian Hale; Janeen Laven; Julu Bhatnagar; J Erin Staples
Journal:  MMWR Morb Mortal Wkly Rep       Date:  2017-09-01       Impact factor: 17.586

  3 in total
  28 in total

1.  Yellow Fever: Factors Associated with Death in a Hospital of Reference in Infectious Diseases, São Paulo, Brazil, 2018.

Authors:  Ana Freitas Ribeiro; Roberta Figueiredo Cavalin; Jamal Muhamad Abdul Hamid Suleiman; Jessica Alves da Costa; Marileide Januaria de Vasconcelos; Ceila Maria Sant'Ana Málaque; Jaques Sztajnbok
Journal:  Am J Trop Med Hyg       Date:  2019-07       Impact factor: 2.345

2.  Yellow fever in two unvaccinated French tourists to Brazil, January and March, 2018.

Authors:  Emma Oliosi; Chantal Serero Corcos; Paulo Feijo Barroso; Alexandre Bleibtreu; Gilda Grard; Bispo Ana Maria De Filippis; Eric Caumes
Journal:  Euro Surveill       Date:  2018-05

Review 3.  [What is verified for travel vaccinations?]

Authors:  Tomas Jelinek
Journal:  Internist (Berl)       Date:  2018-12       Impact factor: 0.743

Review 4.  The continued threat of emerging flaviviruses.

Authors:  Theodore C Pierson; Michael S Diamond
Journal:  Nat Microbiol       Date:  2020-05-04       Impact factor: 17.745

Review 5.  Yellow Fever Virus: Diagnostics for a Persistent Arboviral Threat.

Authors:  Jesse J Waggoner; Alejandra Rojas; Benjamin A Pinsky
Journal:  J Clin Microbiol       Date:  2018-09-25       Impact factor: 5.948

6.  Persistence of yellow fever virus-specific neutralizing antibodies after vaccination among US travellers.

Authors:  Nicole P Lindsey; Kalanthe A Horiuchi; Corey Fulton; Amanda J Panella; Olga I Kosoy; Jason O Velez; Elizabeth R Krow-Lucal; Marc Fischer; J Erin Staples
Journal:  J Travel Med       Date:  2018-01-01       Impact factor: 8.490

Review 7.  Yellow Fever in Travelers.

Authors:  Annelies Wilder-Smith
Journal:  Curr Infect Dis Rep       Date:  2019-10-31       Impact factor: 3.725

8.  Potential yellow fever epidemics in unexposed populations.

Authors:  Duane J Gubler
Journal:  Bull World Health Organ       Date:  2018-05-01       Impact factor: 9.408

Review 9.  What Does the Future Hold for Yellow Fever Virus? (II).

Authors:  Raphaëlle Klitting; Carlo Fischer; Jan F Drexler; Ernest A Gould; David Roiz; Christophe Paupy; Xavier de Lamballerie
Journal:  Genes (Basel)       Date:  2018-08-21       Impact factor: 4.096

10.  International travel between global urban centres vulnerable to yellow fever transmission.

Authors:  Shannon E Brent; Alexander Watts; Martin Cetron; Matthew German; Moritz Ug Kraemer; Isaac I Bogoch; Oliver J Brady; Simon I Hay; Maria I Creatore; Kamran Khan
Journal:  Bull World Health Organ       Date:  2018-04-11       Impact factor: 9.408

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.